Physician profile
Paul Docis
NPI 1790804946
$154.09
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $110 · 2022: $43.92.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mission Pharmacal Company | $29.24 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $28.97 | 2021 | |
| Lilly USA, LLC | $16.54 | 2022 | |
| Abbvie INC. | $15.46 | 2022 | |
| Pfizer INC. | $14.10 | 2021 | |
| Genzyme Corporation | $14.10 | 2021 | |
| Janssen Scientific Affairs, LLC | $12.11 | 2021 | |
| Incyte Corporation | $11.92 | 2022 | |
| Janssen Biotech, INC. | $11.65 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Docis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.